Uteron Pharma : Research for woman future Uteron Pharma : Research for woman future Uteron Pharma : Research for woman future
Uteron Pharma : Research for woman future

2013/01/23 : Watson Acquires Uteron Pharma

Read more


2012/05/2 : Uteron Pharma is contemplating a public offering to finance the (...)

Read more


2012/04/24 : Professor Jean-Michel Foidart has been awarded the Bologne-Lemaire (...)

Read more



Uteron Pharma : Research for woman future

Background

About Uteron Pharma SPRL

Uteron Pharma sprl is a Research & Development oriented company and a subsidiary of Actavis plc. Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, branded generic, Over-the Counter (OTC) and biosimilar products.

Uteron Pharma sprl is designated as one of Actavis’ Centre of Excellence for women’s health delivering product development, cGMP manufacturing of Levosert™ hormonal intra-uterine device and quality & regulatory expertise from a custom-designed facility located in Liège, Belgium. 

The company has successfully developed Levosert™ (levonorgestrel-releasing Intra-Uterine Device), and is currently developing Estetrol (E4) Combination Oral Contraception, a non-invasive adjunctive In Vitro Fertilization selection assay and an early stage treatment for high grade cervical lesions. 

 

About Actavis plc

Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, branded generic, Over-the Counter (OTC) and biosimilar products.

The Company has global headquarters in Dublin, Ireland and Administrative Headquarters in Parsippany, New Jersey, USA.

  • The new Actavis plc is a powerful combination of the highly successful and previously separate Actavis, Inc. (NYSE:ACT) and Warner Chilcott plc (NASDAQ: WCRX).
  • Operating as Actavis Pharma, our generic, branded generic, legacy brands and Over-the-Counter (OTC) business markets more than 750 products globally through operations in more than 60 countries.
  • Actavis Specialty Brands is a global branded specialty pharmaceutical business focused principally in the Women’s Health, Urology, Gastroenterology and Dermatology therapeutic categories.
  • Actavis is committed to developing and marketing biosimilar products in Women’s Health, Oncology and other therapeutic categories.
  • Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
  • Actavis develops and out-licenses generic pharmaceutical products to customers in more than 100 countries outside of the U.S. through its Medis third-party business. 



© 2011 Uteron Pharma - Legal - Privacy policy Designed and Powered by Lusis Communication

Company

Background
History
Location
Management team
Contact us

Products

Levosert™
E4/Progestin OC
Diafert™
Colvir

Production

Market

Newsroom

Uteron Pharma : Research for woman future